Form 4: Kairos Pharma Executive Ramachandran Murali Reports Stock Award

Ramachandran Murali, VP of Research and Development at Kairos Pharma, reports the acquisition of 14,000 restricted stock units.

Summary

• Ramachandran Murali, VP of Research and Development at Kairos Pharma, reported a transaction on January 1, 2025.
• He acquired 14,000 restricted stock units (RSUs) under the 2023 Equity Incentive Plan.
• These RSUs vest in three increments: one-third on January 1, 2025, another third on September 16, 2025, and the final third on September 16, 2026.
• As of the report date, 4,667 RSUs have vested.
• Following the reported transaction, Murali beneficially owns 147,057 shares of common stock, including 9,333 unvested RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the company's future. There are no explicitly negative aspects in the report.

Positives

• The granting of RSUs to a key executive like the VP of Research and Development suggests an investment in the company's future and aligns the executive's interests with those of the shareholders.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

Stock grants to executives are a common practice in the pharmaceutical industry to incentivize performance and retain talent. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Equity compensation is a standard practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Pfizer routinely grant stock options and RSUs to their executives as part of their compensation packages.
• The vesting schedules, typically ranging from three to four years, are designed to align executive incentives with long-term shareholder value.
• The size of the grant is relative to the size of the company and the executive's role.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns executive interests with long-term company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Kairos Pharma, Ramachandran Murali, Restricted Stock Units, RSUs, Beneficial Ownership, Equity Incentive Plan, Vesting